Dyno Therapeutics To Present On Breakthrough Optimized AAV Capsids For Eye And CNS Gene Delivery At ESGCT Annual Congress

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that expand the potential of genetic medicine, today announced a Dyno Scientific Symposium and the presentation of three research abstracts at the upcoming 30^th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) being held October 24-27, 2023 in Brussels, Belgium.

Dyno Scientific Symposium:

Title: “Dyno Therapeutics: NHP-Validated Capsids for Best-in-Class Ocular and CNS Gene Delivery”
Presenter: Eric Kelsic, Ph.D., Co-founder and CEO, Dyno Therapeutics
Date and Time: Wednesday, October 25 from 13:25 to 14:25 CET
Location: Maison de la Poste

Dyno’s scientific symposium will showcase in vivo NHP data on field-leading capsids across the eye and CNS. Dyno’s AI-designed capsids significantly advance gene delivery capabilities, towards unlocking the full potential of genetic medicine.

Research abstracts showcasing Dyno’s capsids:

Title: “Dyno-86m: Cell-Type Resolved Validation of AAV capsids Optimized for Intravitreal Delivery to the Non-Human Primate Retina”
Date and Time: Wednesday, October 25 from 18:15 to 19:30 and Thursday, October 26 from 19:30 to 20:30 CET
Poster/Abstract Number: #P038

Title: “Dyno bCap 1: Single-Cell Characterization of CNS Transduction by Intravenously Administered AAV Capsids in Non-Human Primates”
Date and Time: Wednesday, October 25 from 18:15 to 19:30 and Thursday, October 26 from 19:30 to 20:30 CET
Poster/Abstract Number: #P012

Research abstracts featuring Dyno’s platform capabilities:

Title: “VAEprop: A Generative Machine Learning Approach for Designing High-Performing AAV Capsids for the Non-Human Primate Brain”
Date and Time: Wednesday, October 25 from 18:15 to 19:30 and Thursday, October 26 from 19:30 to 20:30 CET
Poster/Abstract Number: #P076

About Dyno Therapeutics

Dyno Therapeutics is solving the in vivo gene delivery challenge while partnering with gene therapy developers towards maximizing patient impact. Dyno’s platform combines AI with high-throughput experimentation to accelerate the design of AAV capsids with properties that significantly outperform current in vivo gene delivery vectors, with the goal of expanding the range of diseases treatable with genetic medicines. Dyno has partnered with leading gene therapy developers, including Astellas, Novartis, Roche, and Sarepta, and is broadly open to partnering across therapeutic areas. Dyno was founded in 2018 and is located in Watertown, Massachusetts. Visit www.dynotx.com for additional information.

Contacts

Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbrigecommunications.com

First published on Wed, Oct 11, 2023

Enjoyed what you read? Great news – there’s a lot more to explore!

Dive into our content repository of the latest tech news, a diverse range of articles spanning introductory guides, product reviews, trends and more, along with engaging interviews, up-to-date AI blogs and hilarious tech memes!

Also explore our collection of branded insights via informative white papers, enlightening case studies, in-depth reports, educational videos and exciting events and webinars from leading global brands.

Head to the TechDogs homepage to Know Your World of technology today!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs' site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.

Tags:

Dyno Therapeutics Inc. Therapy Developers Artificial Intelligence AI-Designed

Join The Discussion

Emerging Technology

FeaturedEmerging Technology

Emerging Technology

FeaturedEmerging Technology

Emerging Technology

FeaturedEmerging Technology

Emerging Technology